Molecular Devices' Shares Tank 17 Percent After Firm Slashes Q3 Revenue Outlook | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Molecular Devices were down more than 17 percent, or $3.75, at $18.09 in mid-afternoon trading after the company today slashed its revenue outlook for the third quarter by between 8 percent and 12 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.